facebook pixel Phone 212 693 530* *Fixed network call charges according to your tariff Search for your nearest Collection Point

212 693 530*

Collection Points

Phone 212 693 530* *Fixed network call charges according to your tariff

MyPharmaGenes Test

Published: June 14, 2022

The Germano de Sousa Group, in partnership with HeartGenetics, offers MyPharmaGenes® PGx, an innovative pharmacogenetic test—the only one of its kind in Europe—that provides useful information about the body’s response to various medications across five therapeutic areas:

  • Psychiatry,
  • Pain Management,
  • Oncology,
  • Diabetes,
  • Cardiovascular.

Variability in response to medications is a major public health concern. More than 90% of medications are ineffective in more than 50% of patients, and genetic variants that affect the absorption, distribution, metabolism, excretion, and toxicity of medications account for approximately 20 to 30% of the variability in response to medications among individuals. Research into the human genome has been enabling a more patient-centered clinical practice, including decision-making based on genetic and molecular information. The pharmacogenetic approach is therefore essential, and the MyPharmaGenes® test emerges as a key component in the implementation of personalized medicine.

The MyPharmaGenes® PGx test uses iPLEX MassArray technology, which guarantees 99% accuracy and sensitivity, and analyzes genetic variants associated with the metabolism of and response to certain medications—all of which are scientifically validated and have proven clinical utility. It evaluates more than 100 drugs, 32 genes, and 88 genetic variants and CNVs of CYP2D6 and hybrid structures, which are of great importance for the correct definition of a patient’s phenotype.

As a clinical decision-support tool for identifying the safest and most effective drug, it enables the prescribing of more appropriate medication dosages, the evaluation of a patient’s response to treatment, and the prevention of adverse drug reactions. It was developed to support patients who are starting treatment, who are not achieving therapeutic goals, and/or who are experiencing moderate to severe adverse effects from their current therapy, as well as any individual seeking information about their genetic predisposition to drug response.

In Greater Lisbon, the test can be performed at the Germano de Sousa Group’s Headquarters and Central Laboratory (Lisbon Technology Park), while in the Northern region it is available at the Germano de Sousa Group’s Porto Laboratory (Trindade – Domus Building). The test is supported by an interactive web app where patients can manage their own medication portfolio, record medications that have caused adverse effects, and obtain information about medications that may or may not be recommended based on their known genetic information.

The Germano de Sousa Group thus reinforces its ongoing monitoring of the challenges and advancements in medicine worldwide, where genetic and genomic approaches are playing an increasingly important role, making this knowledge available to physicians and their patients.

If you have any questions, please contact us.
We'll be happy to help.

CLINICAL PATHOLOGY LABORATORY

CLINICAL PATHOLOGY LABORATORY
EMAIL

Phone 212 693 530*

*Fixed network call charges according to your tariff

Related Clinical Analyses: